Experienced in Pleuropulmonary Blastoma

Dr. Jason E. Tache

Hematology Oncology | Hematology | Oncology
South Florida Oncology And Hematology Consultants LLC
8200 W Sunrise Blvd, Bldg C, 
Plantation, FL 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Offers Telehealth
Experienced in Pleuropulmonary Blastoma
South Florida Oncology And Hematology Consultants LLC
8200 W Sunrise Blvd, Bldg C, 
Plantation, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jason Tache is a Hematologist Oncology specialist and a Hematologist in Plantation, Florida. Dr. Tache is rated as an Experienced provider by MediFind in the treatment of Pleuropulmonary Blastoma. His top areas of expertise are Thrombotic Thrombocytopenic Purpura, Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Venous Thromboembolism (VTE), and Orchiectomy. Dr. Tache is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Memorial Hospital Pembroke
Westside Regional Medical Center
Languages Spoken
English
Hebrew
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

SOUTH FLORIDA ONCOLOGY AND HEMATOLOGY CONSULTANTS LLC
8200 W Sunrise Blvd, Bldg C, Plantation, FL 33322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma
Enrollment Status: Recruiting
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: TAB004, Toripalimab
Study Phase: Phase 1
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
Enrollment Status: Recruiting
Publish Date: April 07, 2023
Intervention Type: Drug
Study Drugs: DPX-Survivac, Pembrolizumab, CPA
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
Enrollment Status: Terminated
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drugs: Tamibarotene, Venetoclax, Azacitidine
Study Phase: Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Enrollment Status: Terminated
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: MT-3724
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

1 Total Publications

An Extremely Rare Manifestation of Multiple Myeloma: An Immunoglobulin D Secreting Testicular Plasmacytoma.
An Extremely Rare Manifestation of Multiple Myeloma: An Immunoglobulin D Secreting Testicular Plasmacytoma.
Journal: Cureus
Published: August 29, 2017
Similar Doctors
Distinguished in Pleuropulmonary Blastoma
Dr. Edgardo S. Santos
Hematology Oncology | Hematology | Oncology
Distinguished in Pleuropulmonary Blastoma
Dr. Edgardo S. Santos
Hematology Oncology | Hematology | Oncology

The Oncology Institute Fl, LLC

500 Se 17th St 1st Floor, Suite 100, 
Fort Lauderdale, FL 
 (9.2 miles away)
754-202-3460
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Edgardo Santos is a Hematologist Oncology specialist and a Hematologist in Fort Lauderdale, Florida. Dr. Santos is rated as a Distinguished provider by MediFind in the treatment of Pleuropulmonary Blastoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Squamous Cell Lung Carcinoma. Dr. Santos is currently accepting new patients.

Distinguished in Pleuropulmonary Blastoma
Dr. Estelamari A. Rodriguez
Hematology Oncology | Hematology | Oncology
Distinguished in Pleuropulmonary Blastoma
Dr. Estelamari A. Rodriguez
Hematology Oncology | Hematology | Oncology

University Of Miami

1475 Nw 12th Ave, 
Miami, FL 
 (25.0 miles away)
305-689-8648
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Estelamari Rodriguez is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Rodriguez is rated as a Distinguished provider by MediFind in the treatment of Pleuropulmonary Blastoma. Her top areas of expertise are Squamous Cell Lung Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Bone Marrow Aspiration. Dr. Rodriguez is currently accepting new patients.

Distinguished in Pleuropulmonary Blastoma
Dr. Federico Albrecht
Hematology Oncology | Hematology | Oncology
Distinguished in Pleuropulmonary Blastoma
Dr. Federico Albrecht
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Oncology LLC

8900 N Kendall Dr, 
Miami, FL 
 (32.5 miles away)
786-596-2000
Languages Spoken:
English, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Federico Albrecht is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Albrecht is rated as a Distinguished provider by MediFind in the treatment of Pleuropulmonary Blastoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and ALK-Positive Non-Small Cell Lung Cancer. Dr. Albrecht is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tache's expertise for a condition
ConditionClose
      View All 11 Advanced Conditions
      View All 85 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile